Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of NEU-111 in Healthy Volunteers
NCT06500442Phase 1Completed
- Sponsor
- Neuron23
- Start
- Sep 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in immune-mediated inflammatory diseases (IMID), psoriasis, ulcerative colitis (UC) and 5 more comparing NEU-111 with Placebo (2 arms). Primary endpoint: Safety and tolerability of single and multiple oral doses of NEU-111 up to 10 days. Started Sep 2024; status: completed.
02
Drugs
NEU-111
03
Conditions
immune-mediated inflammatory diseases (IMID)psoriasisulcerative colitis (UC)Crohn's diseasesystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06500442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500442.